Article Details
Retrieved on: 2025-09-08 18:42:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... Roche's Ocrevus. - A Phase 3 trial for subcutaneous BRIUMVI, offering self-administration, aims to capture 40% of RMS patients preferring ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here